IPO registrations (S-1, F-1) · Registrants
Juno Therapeutics, Inc.
- SEC CIK
- 1594864 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2014-11-17, last 2014-12-18; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 2014-12-19; declared effective 2014-12-18
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 400 DEXTER AVENUE NORTH, SUITE 1200, Seattle, WA 98109
- EIN
- 46-3656275
- EDGAR entity type
- operating
- Insiders and CEO pay
- Juno Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $21.00–$23.00 per share (S-1/A filed 2014-12-18)
- Final price
- $24.00 per share, above the range (424B4 filed 2014-12-19, an initial public offering)
- Shares sold
- 11,022,917
- Gross proceeds
- $264,550,008 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol JUNO
- Lead underwriters
- Morgan Stanley (3,582,448 shares); J.P. Morgan (3,582,448 shares); Goldman Sachs (3,306,875 shares)
- Syndicate
- Leerink Partners (551,146)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: JUNO THERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Juno Therapeutics, Inc. Fuzzy (name and state)
- Business registration: Juno Therapeutics, Inc. Fuzzy (name and state)
- Business registration: Juno Therapeutics, Inc. Fuzzy (name and state)
- Business registration: JUNO THERAPEUTICS, INC Fuzzy (name and state)
- Business registration: JUNO THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: JUNO THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Political committee (FEC): JUNO THERAPEUTICS POLITICAL ACTION COMMITTEE (JUNOPAC) (connected to JUNO THERAPEUTICS) Fuzzy (name and state)
- Form D issuer: Juno Therapeutics, Inc. EXACT (CIK (EXACT))
- Lobbying client: JUNO THERAPEUTICS, INC. Fuzzy (name and state)
- SEC filer: Juno Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-11-17 | S-1 | S-1 (registration) | Juno Therapeutics, Inc. | 0001193125-14-414077 ↗ |
| 2014-11-24 | S-1/A | S-1/A (amendment) | Juno Therapeutics, Inc. | 0001193125-14-423255 ↗ |
| 2014-12-09 | S-1/A | S-1/A (amendment) | Juno Therapeutics, Inc. | 0001193125-14-436942 ↗ |
| 2014-12-16 | S-1/A | S-1/A (amendment) | Juno Therapeutics, Inc. | 0001193125-14-443418 ↗ |
| 2014-12-18 | S-1/A | S-1/A (amendment) | Juno Therapeutics, Inc. | 0001193125-14-445989 ↗ |
| 2014-12-18 | S-1MEF | S-1MEF (added securities) | Juno Therapeutics, Inc. | 0001193125-14-447155 ↗ |
| 2014-12-18 | EFFECT | EFFECT (declared effective) | Juno Therapeutics, Inc. | 9999999995-14-003736 ↗ |
| 2014-12-19 | 424B4 | 424B4 (final prospectus) | Juno Therapeutics, Inc. | 0001193125-14-447554 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-18 | S-1/A | registration statement | $21.00–$23.00 | $22.00 | 9,250,000 | $203,500,000 | Nasdaq JUNO | 4 | primary document; range, price sentence, shares headline, proceeds computed, cover names 4 | document ↗ |
| 2014-12-19 | 424B4 | final prospectus | $24.00 | 11,022,917 | $264,550,008 | Nasdaq JUNO | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Arch Venture Fund VII LP | TenPercentOwner | 3 | 2014–2016 | ||
| ARCH Venture Partners VII, LLC | TenPercentOwner | 3 | 2014–2016 | ||
| ARCH Venture Partners VII, L.P. | TenPercentOwner | 3 | 2014–2016 | ||
| Barron Hal | Director | 14 | 2014–2018 | ||
| Bishop Hans Edgar | Director,Officer | CEO and President; CEO & President; See Remarks | 18 | 2014–2018 | |
| BRATTON DOUGLAS K | TenPercentOwner | 7 | 2014–2017 | ||
| BYBEE CLINTON | TenPercentOwner | 3 | 2014–2016 | ||
| Cassidy Bernard J | Officer | General Counsel and Secretary; General Counsel & Secretary | 23 | 2014–2018 | |
| CL Alaska, L.P. | TenPercentOwner | 5 | 2014–2017 | ||
| CRANDELL KEITH | TenPercentOwner | 3 | 2014–2016 | ||
| Crestline Investors, Inc. | TenPercentOwner | 5 | 2014–2017 | ||
| Crestline Management, LP | TenPercentOwner | 5 | 2014–2017 | ||
| Crestline SI (GP), L.P. | TenPercentOwner | 5 | 2014–2017 | ||
| EVNIN ANTHONY B | Director | 22 | 2014–2018 | ||
| Frohlich Mark W | Officer | See Remarks | 4 | 2014–2016 | |
| Harr Steve | Officer | CFO & Head, Corp. Development; See Remarks | 17 | 2014–2018 | |
| Klausner Richard | Director | 28 | 2014–2018 | ||
| NELSEN ROBERT | Director; Director,TenPercentOwner | 14 | 2014–2018 | ||
| PIEN HOWARD H | Director | 14 | 2014–2018 | ||
| Tessier-Lavigne Marc | Director | 4 | 2014–2016 | ||
| Wilderotter Mary Agnes | Director | 5 | 2014–2018 | ||
| Levitsky Hyam | Officer | EVP, Research & CSO; See Remarks | 6 | 2015–2017 | |
| Daniel Thomas O | Director | 3 | 2015–2018 | ||
| Azelby Robert | Officer | EVP & Chief Commercial Officer; See Remarks | 17 | 2015–2018 | |
| AGARWAL SUNIL | Officer | President of R & D | 6 | 2017–2018 | |
| VESSEY RUPERT | Director | 1 | 2017 | ||
| FLATLEY JAY T | Director | 6 | 2017–2018 | ||
| LEE ANN L. | Officer | EVP, Technical Operations | 4 | 2017–2018 | |
| Blue Magpie Corp | TenPercentOwner | 1 | 2018 | ||
| CELGENE CORP /DE/ | TenPercentOwner | 1 | 2018 | ||
| Celgene Switzerland LLC | TenPercentOwner | 1 | 2018 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2017-10-05 | Juno Therapeutics, Inc. | Biotechnology | $31,091,407 | $31,091,407 | 1 | 1 |
| 2015-07-14 | Juno Therapeutics, Inc. | Biotechnology | Indefinite | $898,495,324 | 2 | 3 |
| 2014-08-14 | Juno Therapeutics, Inc. | Biotechnology | $133,734,641 | $85,499,985 | 22 | 1 |
| 2014-05-08 | Juno Therapeutics, Inc. | Biotechnology | $97,000,000 | $28,423,971 | 34 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Juno Therapeutics, Inc. | WA | State business registries | name and state |
| Business registration | Juno Therapeutics, Inc. | WA | State business registries | name and state |
| Business registration | Juno Therapeutics, Inc. | WA | State business registries | name and state |
| Business registration | JUNO THERAPEUTICS, INC | WA | State business registries | name and state |
| Business registration | JUNO THERAPEUTICS, INC. | WA | State business registries | name and state |
| Business registration | JUNO THERAPEUTICS, INC. | WA | State business registries | name and state |
| Plan sponsor | JUNO THERAPEUTICS, INC. | WA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Political committee | JUNO THERAPEUTICS POLITICAL ACTION COMMITTEE (JUNOPAC) (connected to JUNO THERAPEUTICS) | WA | Campaign finance (FEC) | name and state |
| Form D issuer | Juno Therapeutics, Inc. | WA | Form D private offerings | CIK (EXACT) |
| Lobbying client | JUNO THERAPEUTICS, INC. | WA | Federal lobbying (LDA) | name and state |
| Patent assignee | Juno Therapeutics, Inc. | WA | Patents (USPTO) | name and state |
| SEC filer | Juno Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Juno Therapeutics, Inc. | WA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | JUNO THERAPEUTICS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), WA first:
- CORIXA CORP WA
- Seagen Inc. WA
- ZYMOGENETICS INC WA
- NS Wind Down Co., Inc. WA
- Adaptive Biotechnologies Corp WA
- LeonaBio, Inc. WA
- Sana Biotechnology, Inc. WA
- Icosavax, Inc. WA
- Intrinsic Medicine, Inc. WA
- Aurion Biotech, Inc. WA
In other datasets, the same topic (Health) in WA:
- Nonprofit: ACUPUNCTURE RELIEF PROJECT (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health